Pacific Biosciences — The Long-Read Revolution

历史时间线

• 2004: Founded by Stephen Turner and others at Cornell/Brown
• 2009: Ships first SMRT (Single Molecule Real-Time) sequencing system
• 2010: IPO on NASDAQ
• 2010s: HiFi (high-fidelity) reads achieve 99.9% accuracy with 10-25Kb read lengths
• 2018: Sequel II system dramatically increases throughput and lowers cost
• 2022: Revio system brings HiFi sequencing to population-scale projects
• 2023-2024: Onso short-read system launch (diversification strategy)

商业模式

• Instrument sales: Revio ($950K), Sequel IIe ($650K) sequencers
• Consumables: SMRT Cells, sequencing kits (recurring revenue)
• Services: Contract sequencing and bioinformatics
• Onso: New short-read platform to compete directly with Illumina

护城河分析

• HiFi accuracy: Unique combination of long reads + high accuracy (99.9%) — Nanopore offers long reads but with higher error rates
• Patents: Core SMRT sequencing technology protected by extensive IP
• Scientific reputation: Gold standard for reference-quality genome assemblies
• Telomere-to-telomere: Essential for the T2T Consortium's complete human genome project

关键数据

• Revenue: $300M+ annually
• Installed base: 500+ sequencers worldwide
• Read lengths: 10-25Kb (HiFi), up to 50Kb+ (CLR mode)
• Accuracy: 99.9% Q30+ for HiFi reads

有趣事实

• PacBio's SMRT sequencing technology observes DNA polymerase in real time at the bottom of zero-mode waveguides — tiny holes smaller than the wavelength of light — a feat of nanofabrication
• The complete human genome (T2T-CHM13), published in 2022, relied heavily on PacBio HiFi reads to fill in the 8% of the genome that short-read sequencing had missed for 20 years